Masked Antibodies & Cytokines as Prodrugs: A Landscape Analysis of Stakeholders, Technologies, Pipelines, Business and Financing -

·5 min read

DUBLIN, October 22, 2021--(BUSINESS WIRE)--The "Masked Antibodies & Cytokines as Prodrugs: A Landscape Analysis of Stakeholders, Technologies, Pipelines, Business and Financing from An Industry Perspective" report has been added to's offering.

Therapeutic antibodies have become a clinically and commercially successful treatment modality with more than 100 antibodies approved for therapy and commercial sales of more than US$ 184 billion in the year 2020. However, systemic administration of monoclonal antibodies or cytokines may induce severe adverse events with mechanism-of-action effects, meaning off-tumor on-target toxicity in healthy tissue. In order to increase the selectivity of antibodies and cytokines at the disease site, antibodies should ignore the target antigen and cytokines the receptor in normal healthy tissue and be preferentially active in the disease region.

The use of antibody prodrugs is one new strategy for more specific tumor targeting of biological therapies. Conventional prodrugs are pharmacologically inactive compounds that are converted into active forms in the body after administration. They can be designed to be activated at the intended site of action, thereby lowering the exposure of normal tissues to active drugs and minimizing toxicity. The most common novel approach to creating antibody prodrugs are protease-activated antibodies that use antigen binding site 'masks'. The mask is typically a recombinant protein extension of the light and/or heavy chain of the antibody that has been designed to block access to the antigen binding site and physically prevent the binding of the antibody to the cognate antigen. A protease substrate sequence is also inserted between the mask and the antibody. When the prodrug antibody enters the tumor microenvironment, upregulated proteases that are common in cancer tissues cleave the substrate sequence, the mask separates from the antibody, and the antibody becomes competent to bind to its target in the tumor. This doesn't happen efficiently in normal tissues because there is insufficient extracellular protease activity to remove the mask. The same principle does apply to prodrug cytokines.

The prodrug concept of masking technologies is an elegant approach to address the selectivity limitations of conventional therapeutic antibodies and cytokines.

The report brings you up-to-date with information about and analysis of

  • Stakeholders in the field: technology and major pharmaceutical companies and investors;

  • Masking technologies: conventional (kinetically controlled); pH-dependent and protease cleavage in the tumor microenvironment

  • Targets of masked antibodies and type of masked cytokine selected for development of masked biologics;

  • Business strategy: pure-play (foundational or converted) masking technology company, diversified technology company, exit options, preferred antibody modality or type of cytokine, investment case;

  • Financing situation of technology companies and key investors in the field;

  • Partnering deals with financial terms;

  • Major pharmaceutical companies: preferences for masking technologies, collaboration, and licensing agreements.

What will you find in the report?

  • Profiles of antibody & cytokine masking technology companies active in the field

  • Description of major pharma's/biotech's role in the field (in-house R&D, partnering and investing)

  • Comprehensive description and analysis of emerging masked antibodies and cytokines

  • Pharmacologic profiles of selected masked antibodies and cytokines

  • Characterization, profiling and state of antibody & cytokine masking technologies

  • Target selection for each antibody masking technology

  • Selection of type of cytokine for each cytokine masking technology

  • Description and analysis of financing round

  • Economic terms of collaboration and licensing deals

  • Sources of financing

Key Topics Covered:

1 Executive Summary

2 Introduction, Overview & Methodology

3 Stakeholder Analysis

4 Profiles of Stakeholders in Masking Technologies

  • Accurus Bioscience

  • Adagene

  • Amunix Pharmaceuticals

  • Ascendis Pharma

  • AskGene Pharma

  • BioAtla

  • Bright Peak Therapeutics

  • CytomX Therapeutics

  • GlycoNEX

  • Harpoon Therapeutics

  • Janux Therapeutics

  • Maverick Therapeutics

  • Meditope Biosciences

  • Molecular Partners

  • Nektar Therapeutics

  • Revitope Oncology

  • SeaGen

  • Shanghai Affinity Biopharmaceutical

  • Tansoar Biotech

  • Trutino Biosciences

  • Werewolf Therapeutics

  • Xilio Therapeutics

  • Zymeworks

  • AbbVie

  • ADC Therapeutics

  • Amgen

  • Astellas Pharma

  • BeiGene

  • Boehringer Ingelheim

  • Bristol Myers Squibb

  • Exelixis

  • I-Mab Biopharma

  • Immunogen

  • Janssen

  • Junshi Biosciences

  • Merck

  • Mitsubishi Tanabe Pharma

  • Pfizer

  • Roche

  • Takeda Pharmaceutical Co

5 Analysis of Masking Technologies

5.1 Origin of Masking Technologies

5.2 Prodrug Antibody Technologies

5.3 Prodrug Cytokine Technologies

5.4 Prodrug Antibody & Cytokine Technologies

6 Profiles of Masking Technologies

6.1 Masking Technologies Applied Only To Antibodies

6.2 Masking Technologies Applied Only To Cytokines

6.3 Masking Technologies Applied to Antibodies & Cytokines

7 Analysis of Pipeline and Masked Antibody & Cytokine Prodrug Candidates

7.1 Introduction

7.2 Analysis of the Pipeline of Masked Antibodies

7.3 Analysis of the Pipeline of Masked Cytokines

8 Profiles of Masked Antibody & Cytokine Product Candidates

8.1 Masked Immuno-Oncology Antibodies

8.2 Masked Antibody-Drug Conjugates

8.3 Masked T-Cell Engaging (TCE) Antibodies

8.4 Masked Interleukin-2 (IL-2) Cytokines

8.5 Masked Interleukin-12 (IL-12) and -15 (IL-15) Cytokines

8.6 Masked Interferon (IFN) Cytokines

9 Business, Financing & Partnering

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

View source version on

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting